Aldeyra Therapeutics (ALDX) Prepaid Assets (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Prepaid Assets came in at $1.3 million in Q1 2026, down 52.39% YoY from $2.7 million in Q1 2025, and down 27.02% on a QoQ basis from $1.7 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Prepaid Assets (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Prepaid Assets data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Prepaid Assets fell 52.39% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 52.39% YoY) and the FY2025 annual result came in at $1.7 million, up 326.92% from the prior year.
- Prepaid Assets retreated to $1.3 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $7.8 million in Q1 2024 to a low of $23685.0 in Q1 2023.
- A 5-year average of $3.5 million and a median of $4.0 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets plunged 99.57% — and 2024, when it soared 32868.53%.
- Tracing ALDX's Prepaid Assets over 5 years: stood at $6.7 million in 2022, then fell by 25.81% to $5.0 million in 2023, then slumped by 91.82% to $408091.0 in 2024, then jumped by 326.92% to $1.7 million in 2025, then declined by 27.02% to $1.3 million in 2026.
- The last three Prepaid Assets figures came in at $1.3 million (Q1 2026), $1.7 million (Q4 2025), and $721650.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 721,650.00 |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.67 Mn |
| Dec 31, 2024 | 408,091.00 |
| Sep 30, 2024 | 3.98 Mn |
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Mar 31, 2023 | 23,685.00 |
| Dec 31, 2022 | 6.72 Mn |
| Sep 30, 2022 | 4.15 Mn |
| Jun 30, 2022 | 4.05 Mn |
| Mar 31, 2022 | 5.49 Mn |
| Dec 31, 2021 | 28,770.00 |
| Sep 30, 2021 | 5.40 Mn |
| Jun 30, 2021 | 6.52 Mn |
| Mar 31, 2021 | 8.63 Mn |